Adrenoleukodystrophy Pipeline Landscape Discussed by GMD in Discounted Research Study Published at MarketPublishers.com02 Jun 2017 • by Natalie Aster
LONDON – Adrenoleukodystrophy (ALD) is a deadly inherited disorder that chiefly influences the growth of the myelin (the substance that insulates some nerve cells) and the adrenal glands – small glands situated atop each kidney; the condition mainly occurs in males.
Abetalipoproteinemia is also a type of ALD (Adrenomyeloneuropathy/Schilder-Addison Complex) Bassen-Kornzweig syndrome is a rare autosomal recessive disease passed down through families in which a person is not able to completely absorb dietary fats through the intestinal tract. The disorder is brought about by a defect in gene that communicates the body to produce lipoproteins (molecules of fat coupled with protein). It is sympotomised by scoliosis, muscular weakness, and a decline of vision as time passes. The treatment of the disease usually involves high-dose vitamin supplements that contain fat-soluble vitamins.
Discounted research report “Adrenoleukodystrophy - Pipeline Review, H1 2017” prepared by Grace Market Data (GMD) is devoted to examining the ALD pipeline landscape.
The research study provides comprehensive, unbiased details about the therapeutics in clinical trials for ALD, coupled with an all-round analysis by development stage, drug target, RoA, MoA, and the kind of molecule. The study sheds light on the descriptive pharmacological effect of the therapeutic agents, its complete R&D history and most recent press releases and news. The research gives a review of the key market participants engaged in the therapeutic development for ALD, and covers the various discontinued and dormant projects. The report canvasses the therapeutics in clinical development by companies/institutes/universities, the molecules made by companies. It identifies and tracks emerging market players and their portfolios.
To find more comprehensive market research studies created by GMD, follow its page at MarketPublishers.com.